ABVC BioPharma Inc Stock

$2.59

18.26% yesterday

Nasdaq, Jun 27, 10:18 pm CET

ISIN

US00091F1066

Symbol

ABVC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts Strategies

ABVC BioPharma Inc Stock price

$2.59

-25.41 90.75% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.40 18.26%

ISIN

US00091F1066

Symbol

ABVC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$44.0m

Enterprise Value

$45.4m

Net debt

$1.4m

Cash

$220.0k

Shares outstanding

15.4m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

86.24 | 10.33

EV/Sales

89.02 | 10.67

EV/FCF

negative

P/B

7.37

Financial Health

Equity Ratio

16.26%

Return on Equity

-399.88%

ROCE

-20.84%

ROIC

Debt/Equity

0.30

Financials (TTM | estimate)

Revenue

$510.0k | $4.3m

EBITDA

$-1.7m | -

EBIT

$-1.7m

Net Income

$-1.8m | $-7.2m

Free Cash Flow

$-1.9m

Growth (TTM | estimate)

Revenue

1,600.00% | 734.51%

EBITDA

82.94% | -

EBIT

82.58%

Net Income

85.66% | -47.35%

Free Cash Flow

41.43%

Margin (TTM | estimate)

Gross

99.90%

EBITDA

-326.61% | -

EBIT

-334.05%

Net

-356.41% | -169.56%

Free Cash Flow

-368.96%

EPS

$-0.12

FCF per Share

$-0.12

Short interest

3.57%

Employees

18.00

Rev per Employee

$30.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

ABVC BioPharma Inc Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a ABVC BioPharma Inc forecast:

3x Hold

50%

3x Sell

50%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a ABVC BioPharma Inc forecast:

Hold

50%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from ABVC BioPharma Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	0.51 0.51	1,600% 1,600% 100%
- Direct Costs	- -	- -
Gross Profit	0.51 0.51	332% 332% 100%
- Selling and Administrative Expenses	2.32 2.32	73% 73% 455%
- Research and Development Expense	0.14 0.14	82% 82% 27%
EBITDA	-1.66 -1.66	83% 83% -325%
- Depreciation and Amortization	0.04 0.04	100% 100% 8%
EBIT (Operating Income) EBIT	-1.70 -1.70	83% 83% -333%
Net Profit	-1.81 -1.81	86% 86% -355%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Company Profile

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of new drugs and medical devices. The company also integrates research achievements from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. It conducts clinical trials of translational medicine for Proof of Concept and out-licenses it to international pharmaceutical companies. Its products include BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia. The company was founded in 1990 and is headquartered in Fremont, CA.

Head office	United States
CEO	Uttam Patil
Employees	18
Founded	1990
Website	abvcpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now